The product designated Wuhu Zhuifeng Powder Veterinary Grade API is supplied as a non-sterile crystalline powder intended for further processing into tablets, injections, capsules, powders, granules, premixes, and solutions. The product name may be followed by a route-based grade or model code in procurement documents, such as an oral, injectable, or premix designation. These grade labels are not pharmacopoeial monographs; they are supply-chain identifiers that must be mapped to the route-specific certificate of analysis. Identity is confirmed by infrared absorption spectrophotometry according to Chinese Veterinary Pharmacopoeia general chapter 0402, and assay is determined by stability-indicating high-performance liquid chromatography. The material is released only after the certificate of analysis has been compared with the intended route because injectable, premix, liquid oral, and solid oral uses impose different critical quality attributes. Published quantitative specifications for the exact Wuhu Zhuifeng Powder lot are limited; the technical profile below therefore describes typical route-based controls that a purchaser should request in the batch documentation.

Manufacturing use across the seven listed dosage forms is not achieved by a single set of release tests. Instead, the API is evaluated with a base profile supplemented by route-specific controls. For tablet and capsule operations, particle size distribution, bulk density, tapped density, and flowability determine whether direct compression, dry granulation, or wet granulation is appropriate. Liquid oral and injectable solutions require solubility, clarity, pH, bioburden, and endotoxin data. Feed premix and oral powders require blend uniformity, segregation tendency, and stability in feed matrices. The powder therefore carries wider documentation than a single-route veterinary API. In downstream manufacturing, the formulation scientist must select the acceptance criteria relevant to the intended process and not use a single set of attributes for all finished products.

What distinguishes Wuhu Zhuifeng Powder from conventional single-route veterinary APIs in downstream processing?

The principal distinction lies in the route-specific release and stability controls. A conventional oral powder API may be released only on assay, loss on drying, and microbial enumeration. For this product to be considered for injectable solutions, the powder must also satisfy bacterial endotoxin limits under USP <85>, bioburden control under USP <61>, and residue-on-ignition limits that protect downstream filters and filling equipment. Published data for this specific configuration is limited; however, the multi-route designation appears in the supplier documentation rather than as a single pharmacopoeial monograph. In practice, procurement specifications should require a route-specific certificate of analysis and a statement of the manufacturing process because the same API lot may be acceptable for tablets but unacceptable for intravenous injection if endotoxin data are absent. Another practical difference is that the powder is marketed with supporting data for a wider range of downstream excipient compatibility than is normally provided for a single-route API. This does not remove the need for formulation-specific forced-degradation studies but reduces the initial screening burden when a veterinary manufacturer evaluates several finished-product lines.

The values in the table are typical acceptance thresholds for a multi-route veterinary API and are not specific batch data for Wuhu Zhuifeng Powder. A batch certificate of analysis must be reviewed for the exact specification. Assay and related substances should also be reported by the manufacturer using a stability-indicating HPLC method; for multi-route powders, the method should be capable of separating oxidative and hydrolytic degradation products that may arise in aqueous or feed matrices. Where the intended use is injectable, the method validation should include limit of quantitation for specified impurities at not more than 0.05% of the active area unless the veterinary monograph sets a higher threshold.

Particle size, bulk density, and compressibility parameters relevant to tablet and granulation workflows

For solid dosage manufacture, particle size distribution is measured by laser diffraction or analytical sieving under USP <786>. A direct compression grade is usually controlled by D10, D50, and D90; a target D50 between 70 µm and 120 µm and D90 not more than 150 µm reduces segregation while retaining adequate flow. Bulk density and tapped density are measured by USP <616>. The Hausner ratio and Carr compressibility index provide numerical thresholds for flow: a Hausner ratio below 1.25 and Carr index below 25% are generally acceptable for direct compression, while higher values require dry granulation or wet granulation. These measurements should be performed at controlled room temperature and 40–60% RH because moisture sorption can alter particle cohesion and die-filling behavior.

At tableting scale, powder flow is evaluated on a rotary tablet press with compression force from 8 kN to 20 kN and dwell time from 20 ms to 200 ms. Tablet weight, hardness, and disintegration are recorded over not less than 100 tablets. Weight variation is assessed according to USP <905>. If the powder is not directly compressible, wet granulation is performed with an aqueous binder such as povidone or pregelatinized starch. In a high-shear granulator, starting parameters are often impeller speed 200 rpm and chopper speed 1500 rpm for a 25 L bowl; water addition is stopped when impeller power reaches a predetermined endpoint or when the granulate forms a cohesive mass. The wet mass is dried in a fluid bed dryer until loss on drying is not more than 3.0% by USP <731>, then milled through a 0.8 mm screen. Granule porosity and compressibility are not fully captured by bulk density; therefore, Heckel analysis or compaction simulators are recommended when optimizing tablet hardness.

Dry granulation by roller compaction is used when the powder is sensitive to moisture or heat. The powder is compressed into ribbons using a roller compactor with roll pressure between 30 bar and 80 bar, roll speed from 3 rpm to 10 rpm, and screen size 1.0 mm. The resulting granules have improved flow and density but may lose some tablet strength due to work hardening. Process validation includes ribbon porosity, granule particle size distribution, and tablet hardness over compression force profiles.

In capsule filling, the powder may require flow aids to maintain consistent fill weight on dosator or tamping-pin equipment. Colloidal silicon dioxide at 0.2–0.5 wt% or pregelatinized starch is typically added to correct flow without altering assay. Capsule fill weight variability is checked across 100 units at machine start, middle, and end of the run to ensure a relative standard deviation below 2%. For oral powders and granules, packaging is performed by weight and unit-dose sachet equipment; blend uniformity is evaluated by sampling 10 locations across a V-blender after 20 min mixing. If the powder is added to flavored oral granules, the blend should be sieved through a 1.0 mm screen to break agglomerates and prevent dose variation in pediatric or companion-animal oral syringes.

Tablet coating with aqueous film-forming polymers such as hypromellose requires the tablet core to have low friability, typically less than 1.0% after 100 revolutions in a Roche friabilator. If the powder particle size is too fine and poorly compressible, the core may erode during coating, causing rough surface and dose loss. Therefore, the core formulation must contain a binder and a disintegrant with filler levels adjusted to the API particle size.

When the powder is selected for injectable solutions, additional bioburden and endotoxin controls apply

In injectable solution manufacturing, the powder is dissolved in Water for Injection in a 316L stainless steel vessel, and the resulting solution is clarified by filtration through a polyethersulfone or polyvinylidene fluoride membrane with a pore size not more than 0.22 µm. The active substance itself is not sterile, so terminal sterilization by autoclaving at 121 °C for 15 min or aseptic filtration must be validated for the specific formulation. Bacterial endotoxin content is required to be not more than 0.25 EU/mg unless the dosage form requires a lower limit, and bioburden should not exceed 100 CFU/g before sterile filtration. Sub-visible particulate matter in the finished injection is tested according to USP <788>; for small-volume parenterals, not more than 6000 particles per container at ≥10 µm and not more than 600 particles per container at ≥25 µm are common acceptance thresholds. For large-volume parenterals, the corresponding USP <788> thresholds are 25 particles per millilitre at ≥10 µm and 3 particles per millilitre at ≥25 µm; the appropriate class must be determined by the final container volume.

For injectable solutions, pH is adjusted with 0.1 M hydrochloric acid or sodium hydroxide after complete dissolution. The solution is held for a maximum hold time determined by validation; commonly, a holding time of not more than 8 h at 20–25 °C is used before terminal sterilization to limit microbial proliferation. If aseptic filling is used, the solution should be sterile-filtered immediately before filling, and filter integrity is verified by bubble point and diffusion tests before and after the fill.

Compatibility of the powder with common veterinary vehicles is a separate limitation. The substance should not be blended with strong oxidising agents unless formulation-specific stability data are generated. In aqueous systems, pH is typically adjusted to 5.5–7.5 with citrate or phosphate buffers if the active ingredient is pH-sensitive. Oxygen-sensitive formulations may require nitrogen blanketing during dissolution and filling. Published data for this specific configuration is limited; therefore, a forced-degradation study under acidic, alkaline, oxidative, thermal, and photolytic conditions is necessary for any new injectable or oral liquid formulation.

Residual solvent and elemental impurity control in multi-route veterinary manufacturing

Residual solvents are controlled according to VICH GL18 or the corresponding Chinese Veterinary Pharmacopoeia chapter. For an API intended for injection, residual solvent limits are typically set to the lowest class-specific value. Elemental impurities are assessed according to the applicable CVP general chapter or USP <232> and USP <233>. Loss on drying is controlled by USP <731>, and residue on ignition by USP <281>. The exact quantitative limits must be obtained from the batch-specific certificate of analysis; the values listed in the accompanying table are representative compendial thresholds and are not a substitute for the manufacturer’s specification. In shared facilities, cleaning validation and carryover limits must also be established because the powder is used across multiple downstream lines; rinse and swab samples are analyzed for the active residue, and residues should be below the acceptable daily exposure-derived limit for the least sensitive target species. The cleaning validation protocol should follow 21 CFR 211.67 or equivalent veterinary GMP requirements.

Method transfer for assay and related substances should follow USP <1225> or the applicable CVP chapter. The receiving laboratory should demonstrate comparable precision by analyzing three spiked or retained samples across three days; intermediate precision should be below 2% relative standard deviation for assay and below 10% relative standard deviation for impurities at the specification limit. This is particularly important when the powder is used in seven dosage forms because different sample matrices—tablet cores, capsule blends, aqueous solutions, and feed premixes—can shift chromatographic recovery and require matrix-specific validation.

In feed premix operations, the powder is first blended with an inert carrier such as calcium carbonate, rice hulls, or ground maize cob before addition to complete feed. Segregation is reduced by matching particle size and bulk density between API and carrier; a coefficient of variation below 5% after 10 min mixing is a common in-process control. The active content in finished feed is then assayed by HPLC after extraction; recovery in final feed is typically expected to fall between 90% and 110% of label claim unless the feed additive monograph specifies otherwise. This is relevant because premix homogeneity directly affects the dose consumed by the animal and may shift with vibration during transport. If the powder is used in a mineral or vitamin premix, cholecalciferol or trace mineral sources may require segregation from the API to avoid moisture uptake and potency loss.

Premix stability in animal feed is evaluated at 25 °C/60% RH and 40 °C/75% RH for up to 6 months. The active substance should not be mixed directly with acidic mineral supplements unless a compatibility study demonstrates recovery above 90% of label claim for the intended shelf life. Pelleted feed manufacturing may expose the premix to conditioning temperatures of 70–85 °C and moisture 12–17%; losses depend on the heat sensitivity of the active ingredient and must be verified by extrusion or pelleting trials.

For oral solutions, the powder is dissolved in purified water or a buffered vehicle and filled into amber glass or high-density polyethylene bottles. The pH, appearance, and chemical stability are monitored at 25 °C/60% RH and 40 °C/75% RH according to VICH GL3 as applicable. For multi-dose oral solutions, antimicrobial preservatives are selected after challenge testing using USP <51>; the preservative must be compatible with the API and must not cause precipitation. Precipitation is evaluated by visual inspection and light obscuration particle counting after 24 h and 7 d at room temperature. These liquid-route data are not required for tablets or capsules, which further illustrates the difference between this multi-route API and a conventional single-route powder.

Oral liquid manufacturing also requires viscosity measurement if polymer suspending agents are used. A Brookfield viscometer at 25 °C with spindle speed 60 rpm is used to ensure that the product can be poured or administered through a dosing syringe. If the powder is supplied as a crystalline solid, the solution may require a cosolvent such as propylene glycol or glycerol; the final content of cosolvent is limited by species-specific tolerances and should be justified in the target animal.

Batch-to-batch variance is controlled by the manufacturer through the release data. The formulation scientist should request particle size distribution, bulk density, tapped density, residual solvent, and related substances trends over at least 3 consecutive batches before fixing tablet press parameters or injection filling lines. Published data for this specific configuration is limited; therefore, the exact numerical ranges in this text are starting points based on common veterinary API handling practices and must not replace the approved specification.